Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Portfolio firm Orchestra BioMed closes $110 million Series D funding round, and plans to list on Nasdaq through venture of RTW-sponsored firm Health Sciences Acquisitions Corp 2.
Equity financing and business merger is expected to generate at least $180 million in proceeds, which will go toward funding the combined firm into 2026.
Current stock price: $1.00
12-month change: down 52%
Copyright 2022 Alliance News Limited. All Rights Reserved.